FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sydney Salmon

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Tumor Cells, Cultured

Physiology

Drug Resistance

Procedures

Activities & Behaviors

Drug Evaluation

Co-author Network

Publications

TOP 3
George S Watts; Bernard W Futscher; RB Isett; Mary Gleason-Guzman; M W Kunkel; Sydney E Salmon
cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways.
David S Alberts; Alton V Hallum; M Stratton-Custis; Dava J Garcia; Mary Gleason-Guzman; Sydney E Salmon; P Santabarbara; Eric J Niesor; S Floret; Craig L Bentzen
Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug.
Charles W Taylor; Robert T Dorr; PT Fanta; Evan M Hersh; Sydney E Salmon
A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sydney Salmon (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2001: George S Watts; Bernard W Futscher; RB Isett; Mary Gleason-Guzman; M W Kunkel; Sydney E Salmon
cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways.
The Journal of pharmacology and experimental therapeutics 2001;299(2):434-41.
2001: David S Alberts; Alton V Hallum; M Stratton-Custis; Dava J Garcia; Mary Gleason-Guzman; Sydney E Salmon; P Santabarbara; Eric J Niesor; S Floret; Craig L Bentzen
Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1246-50.
2001: Charles W Taylor; Robert T Dorr; PT Fanta; Evan M Hersh; Sydney E Salmon
A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2001;47(1):83-8.
2000: Mark A Nelson; Michael D Radmacher; R Simon; Mikel Aickin; J Yang; L Panda; JC Emerson; D Roe; L Adair; F Thompson; Jerry Bangert; S P Leong; Raymond M Taetle; Sydney E Salmon; Jeffrey M. Trent
Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases.
Cancer genetics and cytogenetics 2000;122(2):101-9.
1999: Bhashyam S Iyengar; Robert T Dorr; David S Alberts; Evan M Hersh; Sydney E Salmon; William A Remers
Novel antitumor 2-cyanoaziridine-1-carboxamides.
Journal of medicinal chemistry 1999;42(3):510-4.
1998: Bradley J Monk; David S Alberts; Robert A Burger; PT Fanta; Alton V Hallum; Kenneth Hatch; Sydney E Salmon
In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
Gynecologic oncology 1998;71(2):308-12.
1998: Sydney E Salmon; John J Crowley; S P Balcerzak; R W Roach; Sarah A Taylor; Saul E Rivkin; Wolfram E Samlowski
Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):890-6.
1998: Thomas P Miller; E M Chase; Robert T Dorr; William S Dalton; Kit S Lam; Sydney E Salmon
A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease.
Anti-cancer drugs 1998;9(2):135-40.
1997: Q Lou; M E Leftwich; R T McKay; Sydney E Salmon; L Rychetsky; Kit S Lam
Potent pseudosubstrate-based peptide inhibitors for p60(c-src) protein tyrosine kinase.
Cancer research 1997;57(10):1877-81.
1997: Garth Powis; Alfred Gallegos; Robert T Abraham; Curtis L Ashendel; Leon H Zalkow; Robert T Dorr; Katerina Dvorakova; Sydney E Salmon; S Harrison; J Worzalla
Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues.
Cancer chemotherapy and pharmacology 1997;41(1):22-8.
1997: David S Alberts; PT Fanta; K L Running; L P Adair; Dava J Garcia; R Liu-Stevens; Sydney E Salmon
In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Cancer chemotherapy and pharmacology 1997;39(6):493-7.
1997: Charles W Taylor; William S Dalton; K Mosley; Robert T Dorr; Sydney E Salmon
Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer.
Breast cancer research and treatment 1997;42(1):7-14.
1996: Sydney E Salmon; R H Liu-Stevens; Y Zhao; Michal Lebl; V Krchñák; K Wertman; N Sepetov; Kit S Lam
High-volume cellular screening for anticancer agents with combinatorial chemical libraries: a new methodology.
Molecular diversity 1996;2(1-2):57-63.
1996: M R Modiano; P Villar-Werstler; J Crowley; Sydney E Salmon
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):974-7.
1996: Robert T Dorr; Katerina Dvorakova; K Snead; D S Alberts; Sydney E Salmon; George R Pettit
Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor.
Investigational new drugs 1996;14(2):131-7.
1995: F H Thompson; JC Emerson; S Olson; R Weinstein; S A Leavitt; S P Leong; Scott S Emerson; Jeffrey M. Trent; Mark A Nelson; Sydney E Salmon
Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes.
Cancer genetics and cytogenetics 1995;83(2):93-104.
1994: M Federico; D S Alberts; D J Garcia; J Emerson; P Fanta; R Liu; Sydney E Salmon
In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Gynecologic oncology 1994;55(3 Pt 2):S156-63.
1994: Sydney E Salmon; J J Crowley; Thomas M Grogan; P Finley; R P Pugh; Bart Barlogie
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(11):2405-14.
1994: Sydney E Salmon; Evan M Hersh
Sensitivity of multiple myeloma to imexon in the human tumor cloning assay.
Journal of the National Cancer Institute 1994;86(3):228-30.
1993: Thomas M Grogan; C M Spier; Sydney E Salmon; M Matzner; J Rybski; R S Weinstein; R J Scheper; William S Dalton
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy.
Blood 1993;81(2):490-5.
1993: JC Emerson; Sydney E Salmon; W Dalton; D L McGee; JM Yang; F H Thompson; Jeffrey M. Trent
Cytogenetics and clinical correlations in breast cancer.
Advances in experimental medicine and biology 1993;330():107-18.
1993: M Lehnert; Scott S Emerson; William S Dalton; R de Giuli; Sydney E Salmon
In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance.
Journal of the National Cancer Institute. Monographs 1993;(15):63-7.
1992: F J Feo-Zuppardi; Charles W Taylor; K Iwato; M H Lopez; Thomas M Grogan; A Odeleye; Evan M Hersh; Sydney E Salmon
Long-term engraftment of fresh human myeloma cells in SCID mice.
Blood 1992;80(11):2843-50.
1992: William S Dalton; Sydney E Salmon
Drug resistance in myeloma: mechanisms and approaches to circumvention.
Hematology/oncology clinics of North America 1992;6(2):383-93.
1992: D S Alberts; N Mason-Liddil; D Stock-Novack; R V O'Toole; T M Abbott; Sydney E Salmon
A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study.
American journal of clinical oncology 1992;15(2):146-9.
1992: C W Taylor; R Lui; P Fanta; Sydney E Salmon
Effects of suramin on in vitro growth of fresh human tumors.
Journal of the National Cancer Institute 1992;84(7):489-94.
1991: Sydney E Salmon; J Beckord; R P Pugh; Bart Barlogie; J Crowley
alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
Seminars in oncology 1991;18(5 Suppl 7):33-6.
1991: Thomas P Miller; S Dahlberg; Sydney E Salmon; S K Williamson; R J Belt; B W Dana; Richard I Fisher
Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1204-9.
1991: Sydney E Salmon; William S Dalton; T M Grogan; P Plezia; M Lehnert; D J Roe; Thomas P Miller
Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.
Blood 1991;78(1):44-50.
1991: K H Hanson; J Crowley; Sydney E Salmon; M Keppen; T J Braun; J D Bonnet
Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
Anti-cancer drugs 1991;2(3):247-50.
1991: D S Alberts; Robert T Dorr; T P Wunz; William A Remers; Janine G Einspahr; R Liu; Sydney E Salmon
In vitro cytotoxicity against fresh human tumors and P388 leukemia predicts the differential in vivo activity of a series of anthracene anticancer drugs.
Anti-cancer drugs 1991;2(1):69-77.
1991: Gregory D Pennock; William S Dalton; W R Roeske; C P Appleton; K Mosley; P Plezia; Thomas P Miller; Sydney E Salmon
Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration.
Journal of the National Cancer Institute 1991;83(2):105-10.
1991: M Lehnert; William S Dalton; Denise Roe; Scott S Emerson; Sydney E Salmon
Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model.
Blood 1991;77(2):348-54.
1991: Thomas P Miller; Thomas M Grogan; W S Dalton; C M Spier; R J Scheper; Sydney E Salmon
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(1):17-24.
1990: Sydney E Salmon; D Tesh; J Crowley; S Saeed; P Finley; M S Milder; L F Hutchins; C A Coltman; J D Bonnet; B Cheson
Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(9):1575-84.
1990: Sydney E Salmon
Recent advances in the management of lung and breast cancer. Future directions.
Seminars in oncology 1990;17(4 Suppl 7):50-2.
1990: E H Kraut; J J Crowley; Michael R Grever; M D Keppen; J D Bonnet; HE Hynes; Sydney E Salmon
Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study.
Investigational new drugs 1990;8(2):199-200.
1990: P Scuderi; L Woo; Anita S Chong; R Liu; Sydney E Salmon
Modification of the clonogenic assay for the detection of lymphokine activated killer cell activity.
Journal of immunological methods 1990;128(1):119-26.
1990: Charles W Taylor; Thomas M Grogan; Sydney E Salmon
Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms.
Blood 1990;75(5):1114-8.
1990: B G Durie; D Stock-Novack; Sydney E Salmon; P Finley; J Beckord; J Crowley; C A Coltman
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.
Blood 1990;75(4):823-30.
1990: Charles W Taylor; Sydney E Salmon; W G Satterlee; A B Robertone; T M McCloskey; M T Holdsworth; P M Plezia; D S Alberts
A phase I and pharmacokinetic study of intravenous vinzolidine.
Investigational new drugs 1990;8 Suppl 1():S51-7.
1989: Sydney E Salmon; B Soehnlen; William S Dalton; Paul Meltzer; P Scuderi
Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines.
Blood 1989;74(5):1723-7.
1989: Sydney E Salmon; R Liu
Effects of granulocyte-macrophage colony-stimulating factor on in vitro growth of human solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(9):1346-50.
1989: Sydney E Salmon; T M Grogan; T Miller; R Scheper; William S Dalton
Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining.
Journal of the National Cancer Institute 1989;81(9):696-701.
1989: W S Dalton; Thomas M Grogan; P S Meltzer; R J Scheper; B G Durie; Charles W Taylor; Thomas P Miller; Sydney E Salmon
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(4):415-24.
1989: William S Dalton; Thomas M Grogan; J A Rybski; R J Scheper; L Richter; J Kailey; Henk J Broxterman; HERBERT PINEDO; Sydney E Salmon
Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation.
Blood 1989;73(3):747-52.
1989: Evan M Hersh; P Scuderi; W J Grimes; A Chong; Jacqueline L Brailey; C R Gschwind; Sydney E Salmon
Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatants.
Cancer immunology, immunotherapy : CII 1989;30(1):65-70.
1988: R T Dorr; Sydney E Salmon; A Robertone; E Bonnem
Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days.
Journal of interferon research 1988;8(6):717-25.
1988: R M Rifkin; Evan M Hersh; Sydney E Salmon
A phase I study of therapy with recombinant granulocyte-macrophage colony-stimulating factor administered by IV bolus or continuous infusion.
Behring Institute Mitteilungen 1988;(83):125-33.
1987: Sydney E Salmon; L Young; P Scuderi; B Clark
Antineoplastic effects of tumor necrosis factor alone and in combination with gamma-interferon on tumor biopsies in clonogenic assay.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(11):1816-21.
1984: J D Bonnet; R Alexanian; Sydney E Salmon; A Haut; D O Dixon
Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Cancer treatment reports 1984;68(3):481-5.
1983: Sydney E Salmon; A Haut; J D Bonnet; M Amare; J K Weick; B G Durie; D O Dixon
Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1983;1(8):453-61.
1983: S E Jones; P N Grozea; E N Metz; A Haut; R L Stephens; F S Morrison; R Talley; J J Butler; Gerald E Byrne; R Hartsock; D Dixon; Sydney E Salmon
Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study.
Cancer 1983;51(6):1083-90.